Even though researchers and clinicians repeatedly expressed the possibility of using PDE inhibitors in asthma therapy due to their effective bronchodilator and anti-inflammatory properties, none of the PDE4 inhibitors has entered the market as asthma therapy in the past three decades [17]. Here, ALDH7A1 is linked to asthma.